Clinical TrialJul 21, 2026, 07:03 AM
Aclarion Presents Positive Nociscan Clinical Data at ASPN Meeting
AI Summary
Aclarion, Inc. announced the presentation of two abstracts featuring its Nociscan technology at the American Society of Pain & Neuroscience (ASPN) Annual Meeting. The presentations highlighted Nociscan's expanding clinical utility and real-world adoption for chronic low back pain. One abstract detailed an ongoing real-world evidence study with 20 patients, demonstrating successful integration of MRS technology into clinical workflows. The second abstract presented a case study where Nociscan guided basivertebral nerve ablation in a patient without classic Modic changes, resulting in 95% pain relief.
Key Highlights
- Two Nociscan abstracts presented at the American Society of Pain & Neuroscience (ASPN) annual meeting.
- First abstract details a real-world evidence study integrating MRS technology into clinical practice with 20 patients.
- Second abstract presents a case study of a 69-year-old male with 95% relief of chronic low back pain.
- Nociscan guided basivertebral nerve ablation in a patient without classic Modic changes on standard MRI.
- Nociscan identified high pain probability at L3-L4 and possibility at L4-L5 in the case study.
- Nociscan demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
- Approximately 266 million people worldwide suffer from degenerative spine disease and low back pain.
Price Impact
More from ACON